Charlotte’s Web, CU-Boulder To Study CBD, CBN Potential
Charlotte’s Web Holdings, Inc., the market leader in hemp CBD wellness products and a Certified B Corporation, has established a collaborative partnership between its CW Labs division on a preclinical sleep and anxiety study with the University of Colorado-Boulder’s REACH (Research and Education Addressing Cannabis and Health) Center.
The scientific investigation uses the company’s full-spectrum hemp formulations with CBN (cannabinol) and CBD (cannabidiol) and levels of THC below 0.3% to examine the impact on anxiety and sleep quality. The Company is the only hemp CBD brand supporting the University of Colorado REACH Center’s milestone study.
There is limited published preclinical or clinical data on phytocannabinoids other than CBD and THC, especially their effect at levels available in commercially sold hemp-derived CBD supplements. There is some anecdotal evidence on the ability of CBN to help with sleep but little substantiated clinical or preclinical evidence to validate these pervasive claims. Long term, it is anticipated that this study will inform future clinical initiatives to better understand how specific ratios of cannabinoids and different delivery formats are effective at supporting improved sleep quality and instilling healthier sleep architecture in humans.
“Charlotte’s Web is committed to advancing science on the benefits and safety of CBD and other hemp phytocannabinoids through rigorous scientific investigations such as this sleep and anxiety study,” said Tim Orr, senior vice president of Charlotte’s Web and president of its CW Labs division, which currently has more than a dozen scientific research studies underway. “We’re honored to team up with CU’s REACH Center to explore the potential impacts of full-spectrum hemp extract with CBD and CBN on anxiety and sleep quality.”
Monika Fleshner, PhD, professor of Integrative Physiology, and a member of the Center for Neuroscience at the University of Colorado – Boulder is the project lead, and this preclinical study will be conducted in her Stress Physiology Laboratory.
“There is a great need for properly controlled experimental studies that are designed to test the potential neural and physiological impacts of hemp-derived phytocannabinoids,” said Fleshner. “With support from CU REACH and Charlotte’s Web, our research will explore both the efficacy and mechanisms of how these substances can affect complex brain-mediated behavior, such as disturbed sleep.”